Antimicrobial Agents and Resistance
Antimicrobial agents are chemical compounds that kill bacteria or inhibit their growth, and they are organised by the cellular target they attack — the cell wall, the ribosome, nucleic-acid synthesis, or metabolic pathways. This area surveys the major antibacterial classes alongside the counterpart phenomenon of antibiotic resistance, the genetic and biochemical means by which bacteria evade these drugs, and the laboratory methods used to measure susceptibility.
Definition
Antimicrobial agents (antibacterial agents) are substances that, at concentrations achievable in the body, selectively inhibit or kill bacteria; antibiotic resistance is the heritable capacity of a bacterial population to grow in the presence of a drug concentration that would normally suppress it.
Scope
The area orients the reader to the principal antibacterial drug classes (beta-lactams, protein-synthesis inhibitors, fluoroquinolones and others), the mechanisms by which bacteria become resistant, and the susceptibility-testing methods that connect a laboratory result to a clinical interpretation. It is a reference and educational overview of how these agents work and how resistance arises; it is not a prescribing or treatment resource.
Sub-topics
Core questions
- What cellular target does each major antibacterial class act on, and is the effect bactericidal or bacteriostatic?
- By what biochemical and genetic routes do bacteria become resistant to each class?
- How is bacterial susceptibility measured in the laboratory and translated into susceptible, intermediate, or resistant categories?
- What is the global scale and clinical significance of antimicrobial resistance?
Key concepts
- Selective toxicity
- Bactericidal versus bacteriostatic activity
- Drug target (cell wall, ribosome, DNA gyrase, folate pathway)
- Minimum inhibitory concentration (MIC)
- Intrinsic versus acquired resistance
- Horizontal gene transfer and mobile genetic elements
- The ESKAPE pathogens
- Antimicrobial stewardship
Mechanisms
Antibacterial classes are grouped by target. Beta-lactams inhibit cell-wall peptidoglycan cross-linking; protein-synthesis inhibitors (macrolides, tetracyclines, aminoglycosides, oxazolidinones) bind the bacterial ribosome; fluoroquinolones inhibit DNA gyrase and topoisomerase IV; and other classes block folate synthesis or membrane integrity. Resistance arises through a limited repertoire of strategies — enzymatic inactivation of the drug, modification or protection of the target, reduced uptake, and active efflux — encoded either by chromosomal mutation or by genes acquired through horizontal transfer on plasmids, transposons, and integrons (Blair et al., 2015; Alekshun & Levy, 2007). Susceptibility testing measures the minimum inhibitory concentration or an equivalent and applies breakpoints to predict clinical response (Jorgensen & Ferraro, 2009).
Clinical relevance
Understanding antimicrobial agents and the resistance that erodes them underpins how laboratories report susceptibility and how clinicians and stewardship programmes interpret those reports. This entry describes the science behind those processes for orientation and study; it does not provide dosing, regimen selection, or individual treatment guidance.
Epidemiology
Antimicrobial resistance is a major global health burden: a systematic analysis estimated that bacterial AMR was associated with roughly 4.95 million deaths and directly attributable to about 1.27 million deaths worldwide in 2019 (Murray et al., 2022). A small set of multidrug-resistant organisms, summarised by the ESKAPE acronym, accounts for a disproportionate share of difficult-to-treat infections (Boucher et al., 2009).
History
The therapeutic era of antibacterials opened with the sulfonamides and with penicillin's clinical introduction in the 1940s, followed by successive waves of new classes through the mid-twentieth century. Resistance was observed almost as soon as each drug was deployed, and the slowing of new-class discovery alongside the spread of resistance determinants reframed antimicrobials as a finite, shared resource (Boucher et al., 2009; Blair et al., 2015).
Key figures
- Karen Bush
- Stuart B. Levy
- Laura J. V. Piddock
Related topics
Seminal works
- blair-2015
- alekshun-levy-2007
- murray-2022
Frequently asked questions
- How are antibacterial drugs classified?
- Most commonly by their cellular target — cell-wall synthesis, protein synthesis, nucleic-acid synthesis, or metabolic pathways — and secondarily by chemical structure and by whether they kill bacteria (bactericidal) or merely inhibit growth (bacteriostatic).
- What is antimicrobial resistance?
- It is the heritable ability of bacteria to survive and grow at drug concentrations that would normally inhibit them, arising from enzymatic drug inactivation, target alteration, reduced uptake, or efflux, and often spread between bacteria by mobile genetic elements.